To recover your password please fill in your email address
Please fill in below form to create an account with us
iSEARCH – Can intrapartum Sildenafil Citrate safely avert the risks of contraction-induced hypoxia in labour? A pragmatic multicentre Phase III randomised controlled trial.
See ANZCTR for full trial details >
|
Trial Summary: |
To determine if women in labour at term receiving oral 50mg Sildenafil Citrate vs. placebo given in ≤3 doses, reduces a primary composite endpoint, determined up to 28 days after birth, of ten perinatal outcomes related to intrapartum hypoxia. |
|
Supported By: |
NHMRC Medical Research Future Fund |
|
Eligibility: |
Women with singleton or twin pregnancies, planning vaginal birth at ≥37 weeks gestation |
|
Registration ID: |
|
|
Participation: |
Australia |
|
Australian Lead Group: |
Mater Research Institute |
|
Status: |
Completed recruitment |
|
Activation: |
September 2021 |
|
Chairs: |
Professor Sailesh Kumar |
|
Contact: |